Table 1.

List of included studies

Study Author, yOutcome ReportedAKI DefinitionSettingSubjects (AKI)CHF (%)IHD (%)Stroke (%)CKD (%)
Blair, 201120MACEAbsolute increase in SCr≥0.3mg/dlOther2021 (279)2021 (100)1425 (71)NA553 (27)
Chawla, 201421MACEAKIN Criteria: Peak SCr during admission at least 1.5–1.9 times higher than baseline or an increase of ≥0.3 mg/dl (stage 1); an increase of at least 2.0–2.9 times baseline (stage 2); or an increase of ≥3.0 times baseline or ≥4.0 mg/dl (stage 3)Other28554 (9633)2829 (10)28554 (100)653 (2)NA
Choi, 201029CHFAKIN Criteria: AKIN 1 – an SCr increase of ≥0.3 mg/dl, or a relative increase of 150%–200%; AKIN 2 – a relative increase of 200%–300%; AKIN 3 – a relative increase >300%, or in individuals with an SCr of ≥4.0 mg/dl, an SCr increase of 0.5 mg/dl from the baselineOther17325 (3060)358 (2)1186 (7)NA1281 (7)
Damman, 200926CHFAbsolute increase in SCr>26.5 mmol/L (>0.3 mg/dl) in combination with >25% increase in SCr between two time pointsOther869 (106)869 (100)364 (42)80 (9)NA
Damman, 201427CHFAbsolute increase in SCr of ≥26.5 mmol/L (≥0.3 mg/dl), together with a relative increase in SCr of ≥25% between baseline and 8 wkOther3595 (229)3595 (100)884 (25)321 (9)NA
Gammelager, 201425Stroke, IHD, CHFKDIGO Criteria: Stage 1 – 1.5–1.9 times increase versus baseline or ≥0.3 mg/dl increase within 48 h; Stage 2 – 2.0–2.9 times baseline; ≥3.0 times baseline or increase in SCr to ≥4.0 mg/dl or initiation of renal replacement therapyPeri-Operative or ICU21556 (4792)02620 (12)01903 (9)
Giacoppo, 201533IHDAbsolute increase of SCr≥0.5 mg/dl or relative increase ≥25% from baseline value within the first 72 h of interventionCIN9512 (1212)NA9512 (100)376 (4)1702 (18)
Goldberg, 200930IHD, CHFTransient mild AKI - In this group, peak SCr during hospital course was ≥0.3–0.49 mg/dl higher than admission SCr, but pre-discharge SCr returned to a level that was <0.3mg/dl higher than admission creatinine; persistent mild AKI– where SCr did not return to <0.3 mg/dl; transient moderate/severe AKI - peak SCr≥0.5mg/dl higher than admission creatinine, but pre-discharge returned <0.5 mg/dl higher than admission SCr; moderate/severe AKI– where SCr did not return to <0.5 mg/dlCIN1957 (294)368 (19)1957 (100)NA338 (17)
Hansen, 201522MACEAKIN Criteria: Stage 1 – Increase in SCr of ≥0.3 mg/dl (26.5 µmol/L) within 48 h OR increase in SCr of 1.5–1.9 times baseline; Stage 2 – Increase in SCr of 2.0–2.9 times baseline; Stage 3 – Increase in SCr of 3.0 times baseline OR increase in SCr to ≥4.0 mg/dl (353.6 µmol/L) and satisfaction of at least stage 1 OR initiation of renal replacement therapyPeri-Operative or ICU4742 (1457)717 (15)2651 (56)282 6)823 (17)
Holzmann, 201336StrokePostoperative SCr that was the highest value during the entire postoperative period. Absolute increases in SCr: stage 1, 0.3–0.5 mg/dl (26–44 μmol/L); stage 2, 0.5–1 mg/dl (44–88 μmol/L); and stage 3, ≥1 mg/dl (≥88 μmol/L)Peri-Operative or ICU23584 (2764)943 (4)23584 (100)04481 (19)
James, 201128Stroke, IHD, CHFAKIN Criteria: AKI stage 1, ≥0.3 mg/dl absolute or 1.5- to 2.0-fold relative increase in SCr; AKI stage 2, >2- to 3-fold increase in SCr; AKI stage 3, >3-fold increase in SCr or SCr≥4.0 mg/dl with an acute rise of >0.5 mg/dlCIN14782 (1420)2253 (15)10617 (72)1096 (7)3543 (24)
Jose, 200614CVD Mortality, IHD, CHFIncrease in SCr>0.3 mg/dl from baselineOther1854 (223)108 (6)1854 (100)NA610 (33)
Kim, 201418CVD Mortality, IHDSCr ≥25% or ≥0.5 mg/dl from baseline within 72 h after contrast exposureCIN297 (55)NA297 (100)31 (10)297 (100)
Lindsay, 200335IHDAn increase in the SCr of ≥50% from baseline after the interventionCIN5967 (208)NA5967 (100)539 (9)0
Metra, 200823MACEA ≥0.3 mg/dl and a≥25% increase in SCr from admissionOther318 (107)318 (100)173 (54)22 (7)NA
Mielniczuk, 200913CVD Mortality, Stroke, IHD, CHFRIFLE Criteria: Decrease in eGFR of ≥25% compared with baselineOther3795 (184)182 (5)3795 (100)223 (6)NA
Narula, 201419CVD MortalityIncrease in SCr of ≥0.5 mg/dl or a 25% relative rise in creatinine, within 48 h after contrast exposureCIN676 (338)75 (11)676 (100)NA138 (20)
Olsson, 201331CHFIncrease in postoperative SCr values: stage 1 – 0.3 to <0.5 mg/dl (26 to <44 μmol/L); stage 2 – 0.5 to <1 mg/dl (44 to <88 μmol/L); and stage 3 - ≥1 mg/dl (≥88 μmol/L)Peri-Operative or ICU24018 (2779)024018 (100)1153 (5)NA
Ozrazgat-Baslanti, 201616CVD MortalityKDIGO Criteria: ≥50% or 0.3 mg/dl increase in SCr relative to the reference value and stratified AKI severity based on the maximum change in SCr during hospitalizationPeri-Operative or ICU45498 (16854)2915 (6)2727 (6)3731 (8)0
Ryden, 201434IHDPostoperative increase in SCr: stage 1 – 0.3–0.5 mg/dl (26–44 μmol/L); stage 2 – >0.5–1 mg/dl (44–88 μmol/L); stage 3 – ≥1.0 mg/dl (≥88 μmol/L)Peri-Operative or ICU27929 (3617)1117 (4)27929 (100)1396 (5)5586 (20)
Shirakabe, 201212CHFRIFLE Criteria: Class R – increase in SCr ≥ 1.5×baseline; Class I – increase in SCr ≥ 2.0×baseline; Class F – increase in SCr ≥ 3.0×baseline or ≥ 4 mg/dl with an acute rise >0.5 mg/dlOther500 (344)500 (100)201 (40)NANA
Tsai, 201532IHDICD-9 CodePeri-Operative or ICU2849 (86)275 (10)281 (10)2698 (95)164 (6)
Uyarel, 200917CVD MortalityAn increase in SCr level ≥ 0.5 mg/dl or ≥ 25% from baseline (admission) within 72 h of radiocontrast administrationCIN2521 (630)154 (6)2521 (100)NANA
Watabe, 201424MACEA ≥0.5 mg/dl and/or ≥25% absolute increase in SCr from baselineCIN1059 (164)151 (14)1059 (100)90 (8)1059 (100)
Wu, 201437StrokeRIFLE Criteria: AKI was defined according to the RIFLE criteriaOther8630 (4315)1011 (12)1305 (15)01029 (12)
  • MACE, major adverse cardiovascular events; SCr, serum creatinine; NA, not applicable; ICU, intensive care unit; CIN, contract induced nephropathy; CVD, cardiovascular disease.